Mupirocin, also known as BACTROBAN, is an antibacterial medication that inhibits RNA synthetase and is used topically to treat impetigo caused by Staphylococcus aureus and Streptococcus pyogenes. It was first approved by the FDA in 1987 and is produced by GlaxoSmithKline. Impetigo is a contagious skin infection that causes blisters and crusts, commonly seen in children. BACTROBAN comes in cream, ointment, or nasal form and is applied directly to the affected area. It is generally well-tolerated, but some people may experience allergic reactions. BACTROBAN is an important tool in managing impetigo as it helps control the spread of infection and promotes healing. Click on the image below to begin the exploration journey of Mupirocin through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!